Poolbeg Pharma Share Discussion Threads

[chica1] 18/9/2024 07:31

Oral Encapsulation is pre clinical so no material value unfortunately.

POLB001 is only Phase 2 ready and generally Phase 2 candidates don't hold much value.

For me they need more lab chemists and less sales people.
Also I don't see the value in an ointment for Behçet's Disease that still has a long road ahead in the approval process

Still holding half my distribution shares in the HOPE they make a breakthrough.

[pogue] 18/9/2024 07:24

Petterr
I assume you are not invested here either due to your avoidance of positives.
Oral encapsulation looking at targeting obesity is being tested this year. That has a large market. Would say that's a good backup to POLB001 which according to the RNS has been tested in animals now with the cancer drugs so moving forward towards human invivo trails.
Looks like everything going well regards near term income.

[peterrr3] 18/9/2024 06:57

A little economical with the truth on the IP IMO. The POLB patent didn't adequately cover what they wanted to target so a new one had to be lodged in August. The AI patent had almost all the claims rejected with no update provided by the company, so they must have agreed and the viral predict received adverse comments on review. So not such a strong IP suite.

[1gw] 18/9/2024 06:42

Cash runway looks to be something over 2 years on 1H cashflow, although it will depend on any plans to scale up further or commit to R&D.

£2.3m ops cash outflow offset by £0.2m investment cash inflow (interest on cash) to give net £2.1m outflow in the 6 months, vs £10.1m cash at end-1H.

[peterrr3] 18/9/2024 06:41

Not many listed have the successful onboarding of staff as a highlight, but as that is the only thing that has been completed flawlessly so I guess why not.

[1gw] 18/9/2024 06:31

There are the normal interim financial statements incl. P&L, balance sheet & cashflow statement.

You need to keep reading beyond the rns highlights statement.

[2350220] 18/9/2024 06:25

Scant financial info this morning.
For the interims, I would have thought that they'd put a bit more meat on the bones.
Any income over the period.
Cash runway etc.
Or am I being naive/too hopeful?
All the best,
John

Oh blimey, I thought it had finished after Skillington doh🙄
Thanks for pointing that out 1gw
John

[peterrr3] 15/9/2024 19:22

Fool gives Poolbeg a pump, no research at all, maybe from a backhander given the lack of news apart from the corporate comms retainers. Plenty of sheep follow this crowd no matter what they spout, so maybe a leg up.https://www.fool.co.uk/2024/09/15/2-exciting-penny-stocks-under-20p-to-consider-buying-today/

[sikhthetech] 13/9/2024 14:03

2350220,

This is the pump/dump gang at their best. They'll trade hundreds of small buys to push the share price higher and make you believe there's investors buying in.

As the pump/dump gang sell, the share price falls, the gang convince gullible PIs to stay invested, 'news soon' etc, so gullible investors buy thinking the price is about to turn...

Once things settle down, the cheerleader will arrive controlling the narrative, telling gullible PIs, in hindsight, what's happened.

The gang will then agree with the cheerleader, rinse and spin.

[2350220] 13/9/2024 10:42

I'm trying Pogue.
John

[pogue] 13/9/2024 10:37

It's in black or white mode you either believe a deal is coming from one or both the pharmas sniffing POLB001 or you dont. It drifts as pharma deals always take time to get agreed. I beleive others dont I guess you beleive as well. Just got to wait and see.

[2350220] 13/9/2024 10:32

I still haven't learnt that old lesson:
Don't try to catch a falling knife!
I kept adding thinking that it's got to turn at some point 🙄
To think, six months ago this was the darling of my portfolio.
John

[pogue] 11/9/2024 21:04

They have brought two Pharma companies in which have brand new very effective cancer drugs. Problem with the drugs is that they cause cytokline storms so can only be used on limited amount of patients as they need to hospitalise those that take ill from the side effect thus are restricted by number of beds available. The pharmas have given POLB drugs to run trials with POLB001. You can work out the rest.

[talkman2] 11/9/2024 20:04

The new board members have hardly set the world alight . Has anything commercial been achieved yet by this company ?

[chica1] 11/9/2024 17:29

Getting a drug past the FDA takes years and is an expensive process.Gamida filed for bankrupsy in April even with an FDA approved drug.Costs about $700 thousand per treatment 😫
The bond holders who now own Gamida are Highbridge Capital which interestingly were the same bondholders at Aegerion.Aegerion were taken over (while in administration) by Amryt pharma. (after Cathal Friel had left btw)
Joe Wiley and Rory Nealon turned Aegerion around (got a Sh1t load of option for their trouble) so they've been given another bite at the cherry.

Undoubtedly Cathal Friel is on the look out for something similar but you need massively deep pockets to pull it off and float in the US.
For me a phase 2 ointment for Behçet's Disease is not the answer but if they do reverse into Silk Road Therapeutics there will be a big capital raise to do phase 3 trials.

[1gw] 11/9/2024 14:39

Good spot, chica1.

[chica1] 11/9/2024 14:21

It is interesting Gamida Cell have an FDA approved Blood Cancer Cell Therapy and Poolbeg have
recently been tweeting about CRS in blood cancer patients on X.

Omidubicel, sold under the brand name Omisirge, is a blood-based cell therapy used for the treatment of blood cancers.[3][4][5] Omidubicel is a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy derived from cord blood.[3]

Now looking at Gamida Cell it's had its own financial issues but maybe there is some kind of collaboration.

[chica1] 11/9/2024 13:51

Look where the A-Team at Amryt Pharma showed up!

BOSTON--(BUSINESS WIRE)--Jun. 18, 2024-- Gamida Cell (the “Company”;), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced new executive leadership following a successful restructuring transaction ("Transaction”) with certain funds managed by Highbridge Capital Management, LLC (collectively, “Highbridge221;) on May 24, 2024. As part of the Transaction, Highbridge invested $30 million of new capital into Gamida Cell, and is expected to provide substantial additional capital to support ongoing operations, including the research and development, manufacturing, and commercialization of its cell therapeutics. Following the Transaction, Gamida Cell now operates as a wholly owned subsidiary of Ayrmid Limited, a UK entity.
To advance the commercialization of Omisirge® (omidubicel-onlv), a NAM-modified cell therapy for allogenic hematopoietic stem cell transplant, Gamida Cell has named industry stalwart Dr. Joe Wiley as Chief Executive Officer, Rory Nealon as Chief Financial Officer, and Sheila Frame as Chief Commercial Officer.

“Gamida Cell has made great strides in advancing potentially curative cell therapies for cancer and has demonstrated the tremendous potential of its life-saving therapies to improve prospects for patients who cannot find appropriate donors,” said Wiley. “With Highbridge's support, I look forward to leading Gamida Cell into its next phase as we work with hospitals across the U.S. to expand access to Omisirge for the patients who need it most."

Wiley, Nealon, and Frame collectively bring more than 80 years of experience in building, growing, and commercializing innovative pharmaceutical treatments globally:

Dr. Joe Wiley founded Amryt Pharma and served as the CEO until it was acquired by Chiesi Farmaceutici in April 2023. Prior to his role at Amryt, Wiley served as the Principal at Sofinnova Ventures and Medical Director at Astellas Pharma, and he held multiple investment management roles following his work as a neurologist.
Rory Nealon was the co-founder, Chief Financial and Operating Officer at Amryt Pharma from 2015 through its acquisition in 2023. Before joining Amryt, he served executive roles at Trinity Biotech, first as the Chief Financial Officer then as the Chief Operations Officer.
Sheila Frame most recently served as President Americas of Amryt Pharma until it’s sale to the Chiesi Farmaceutici in 2023. Frame has spent much of her career in executive positions leading the commercialization and growth of several important pharmaceutical products in oncology, immunology, and rare diseases in the US as well as globally.

[pogue] 29/8/2024 17:21

A post below I made on the ADVFN help board the other day. Hope this post helps clear other peoples new post reminder as well as mine. Next time I will post a '.'

Can ADVFN sort out the issue with threads that keep showing as new posts on my favourites when the new posters are filtered? I even unhide the posts but that makes no difference. I am not going to unfilter then refilter them as that defeats the object of having filter.
I appreciate the ADVFN fix that removed the filtered users from my view of the thread but it has left this one quirk.
Thanks

[sikhthetech] 29/8/2024 15:21

Pogue
"They have more than enough cash for 2 years "

Have they? Have you looked at the cash position and cash burn?
I think there will be a placing by H1 2025.



sikhthetech - 07 May 2024 - 12:14:12 - 3275 of 3439 Poolbeg Pharma - POLB
Placing by H1 2025, ie by end of June next year.

3 years ago they raised £25m

"Oversubscribed fundraise which resulted in an increased raise from £20m to £25m despite some investor scale back"



Last week, they said they have £12.2m cash remaining, as of Dec 31st 2023. That balance figure is 4 months old.

" Cash balance of £12.2 million as at 31 December 2023"



Their admin costs have been increasing and with the new recruits, I think admin costs are now likely to be around £4m pa.

Therefore, as of H1 end 2024, end of next month, I think they will have around £10m cash.

They have had NIL revenue over the past 3 years.

I, therefore, think they will need a placing by end of H1 next year.

[pogue] 29/8/2024 15:05

I keep seeing you as a troll you seem to pick the negatives that I would argue are not there to start with. Let’s see how it plays, pretty sure I am right though.
Try watching the older presentations on Youtube by JS, lots of info in there, he does not spell things out too well so you need to catch info in the questions at the end or by listening carefully to what he says, difficult as he talks very fast.

[peterrr3] 29/8/2024 08:37

No problem Pogue, we will agree to disagree. The presentation is not too far off so we will see what transpires.